Cost‐Effectiveness Analysis of Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia in Portuguese Patients who are Unsuitable for Full-Dose Fludarabine-Based Therapy
Crossref DOI link: https://doi.org/10.1007/s40258-017-0321-2
Published Online: 2017-03-24
Published Print: 2017-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Paquete, Ana Teresa http://orcid.org/0000-0001-7162-1400
Miguel, Luís Silva
Becker, Ursula
Pereira, Catarina
Pinto, Carlos Gouveia
Funding for this research was provided by:
Roche Farmacêutica Química, Lda.
License valid from 2017-03-24